Orbimed Advisors Llc Sells 1,709,620 Shares of Pieris Pharmaceuticals Inc (PIRS) Stock

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $7.35, for a total transaction of $12,565,707.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Monday, December 18th, Orbimed Advisors Llc sold 147,635 shares of Pieris Pharmaceuticals stock. The stock was sold at an average price of $5.70, for a total transaction of $841,519.50.

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) remained flat at $$7.39 during trading on Friday. The company had a trading volume of 207,800 shares, compared to its average volume of 432,188. The firm has a market cap of $331.03, a P/E ratio of -10.12 and a beta of -76.25. Pieris Pharmaceuticals Inc has a 52-week low of $1.66 and a 52-week high of $7.90.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. The business had revenue of $3.93 million for the quarter, compared to analyst estimates of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 179.74% and a negative return on equity of 407.61%. The business’s revenue for the quarter was up 400.3% compared to the same quarter last year. analysts expect that Pieris Pharmaceuticals Inc will post -0.72 earnings per share for the current fiscal year.

A number of research analysts have weighed in on the stock. HC Wainwright set a $9.00 target price on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 2nd. ValuEngine cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub upgraded shares of Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Pieris Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $9.00.

A number of institutional investors have recently bought and sold shares of PIRS. Schwab Charles Investment Management Inc. bought a new position in shares of Pieris Pharmaceuticals in the 2nd quarter worth $292,000. Rhumbline Advisers bought a new position in shares of Pieris Pharmaceuticals in the 2nd quarter worth $184,000. State of Wisconsin Investment Board bought a new position in shares of Pieris Pharmaceuticals in the 2nd quarter worth $132,000. Bank of New York Mellon Corp bought a new position in shares of Pieris Pharmaceuticals in the 2nd quarter worth $359,000. Finally, Teachers Advisors LLC bought a new position in shares of Pieris Pharmaceuticals in the 2nd quarter worth $308,000. 50.45% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/01/12/pieris-pharmaceuticals-inc-pirs-major-shareholder-orbimed-advisors-llc-sells-1709620-shares.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply